World Journal of Diabetes · 2022 · 22 citations · 17 references
Life SciencesBiochemistryNutritional SciencesMetabolic PhysiologyMetabolic RegulationMetabolismCarbohydrate MetabolismGut MicrobiotaInsulin ResistanceLipid MetabolismMetabolic PathwaysAdipose Tissue LipogenesisAdipose Tissue LipolysisGut Microbiota EffectsMetabolic Disease EtiologyMetabolomic ChangesMicrobiome-associated MetabolitesMicrobiota-derived MetabolitesSkeletal Muscle Glucose Uptake
The gut microbiota plays a key role in metabolic diseases. Gut-microbiota-derived metabolites are found in different dietary sources, including: Carbohydrate (acetate, propionate, butyrate, also known as short-chain fatty acids, as well as succinate); protein (hydrogen sulfide, indole, and phenylacetic acid); and lipids (resveratrol-, ferulic acid-, linoleic acid-, catechin- and berry-derived metabolites). Insulin resistance, which is a global pandemic metabolic disease that progresses to type 2 diabetes mellitus, can be directly targeted by these metabolites. Gut-microbiota-derived metabolites have broad effects locally and in distinct organs, in particular skeletal muscle, adipose tissue, and liver. These metabolites can modulate glucose metabolism, including the increase in glucose uptake and lipid oxidation in skeletal muscle, and decrease in lipogenesis and gluconeogenesis associated with lipid oxidation in the liver through activation of phosphatidylinositol 3-kinase - serine/threonine-protein kinase B and AMP-activated protein kinase. In adipose tissue, gut-microbiota-derived metabolites stimulate adipogenesis and thermogenesis, inhibit lipolysis, and attenuate inflammation. Importantly, an increase in energy expenditure and fat oxidation occurs in the whole body. Therefore, the therapeutic potential of current pharmacological and non-pharmacological approaches used to treat diabetes mellitus can be tested to target specific metabolites derived from intestinal bacteria, which may ultimately ameliorate the hyperglycemic burden.
17
A metagenome-wide association study of gut microbiota in type 2 diabetes
Junjie Qin, Yingrui Li, Zhiming Cai et al. · Nature · 2012 · 7K citations · Full text
Gut metagenome in European women with normal, impaired and diabetic glucose control
Fredrik Karlsson, Valentina Tremaroli, Intawat Nookaew et al. · Nature · 2013 · 3.1K citations
Statin therapy is associated with lower prevalence of gut microbiota dysbiosis
Sara Vieira‐Silva, Gwen Falony, Eugeni Belda et al. · Nature · 2020 · 516 citations · Full text